eligible ages (years): 2.0-20.0,  All  Systemic-Onset Juvenile Idiopathic Arthritis SO-JIA (Edmonton's revision of Durban's consensus conference criteria) Age: at least 2 years and less than 20 years at treatment initiation Disease duration of at least 6 months Failure of corticosteroid treatment or requirement for corticosteroid treatment at a daily dose equal to or over 0.3 mg/kg (10 mg in patients whose weight is over 34 kg) Active and severe systemic symptoms and/or arthritis as assessed by an experienced pediatric Rheumatologists, with at least 3 of the following when assessing Giannini's core-set items: 1) physician global assessment of disease activity of at least 20/100; 2) parent/patient assessment of disease effect on overall well-being of at least 20/100; 3) functional disability with a Children Health Assessment Questionnaire (CHAQ, Ref [9]) score equal to or higher than 0.375/3; 4) 2 joints or more with active arthritis 5) 2 joints or more with non-irreversible limited range of motion (irreversible limited range of motion will be defined by radiological evidence of irreversible joint damage and ankylosis) 6) erythrocyte sedimentation rate (ESR) equal to or higher than 20 In the absence of disease-related fever, either CRP or first hour ESR or both have to be over the upper limit of normal values so that treatment effect on the systemic part of the disease can be objectively evaluated Patients with polyarthritis (at least 5 joints with inflammation and/or limitation of motion) will be eligible for this study only if at least 50% of the affected joints do not present radiological evidence of irreversible damage Informed consent signed by the parents or the person legally responsible for the patient if the patient is less than 18, and by the patient if old enough Teenager girls or young women with childbearing potential must use a contraceptive method (including abstinence tuberculin test performed before Day 1 and must either be negative or positivity must be related to previous immunization and of normal intensity according to the investigator's judgment  Previous treatment with IL-1Ra intra-articular injection or change in the doses of non-steroidal anti-inflammatory drugs and corticosteroids in the 4 weeks preceding the initiation of anakinra treatment Treatment with another immunosuppressive or disease-modifying drugs that could not be stopped before (for a duration depending on the drug pharmacokinetic properties) Contra-indication to the use of anakinra including ongoing active infection or allergy to E Coli's derivate or other components of the drug Previous history of malignancy or heart insufficiency Patients with asthma require to be previously assessed by a pneumonologist Obvious need of therapeutic intervention before study completion such as surgery, intra-articular injection, life vaccine administration Any of the following: leucocyte counts < 3.6 x 10e9/L, polymorphonuclear neutrophil counts < 1.5 x 10e9/L, platelets < 150 000/mm3, serum creatinin > 1.5 the upper limit of normal range for age, serum alanine and aspartate transaminases > 2 times the upper limit of the normal range, serum bilirubin > 2 times the upper limit of the normal range


A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

eligible ages (years): 0.0-20.0,  All  Group A Beta Hemolytic Streptococcal (GAS) Infection All students (approximately 225-250) attending four classes in four rural schools, grades 2-5, in rural villages near Chandigarh, and all students in classes 2-6 approximately 225-250 attending one rural village school near Vellore were asked to participate Approximately an equal number of boys and girls participated Selection of the schools for the study was determined by such factors as the accessibility to a rural regional clinic, housing facilities for medical staff, and passable tertiary roads to the villages and the schools  All volunteers had a history of acute rheumatic fever and acute glomerulonephritis and evidence of rheumatic fever and rheumatic heart disease on physical examination at the initial survey were excluded from the study Excluded also was a child with a compromising illness such as cystic fibrosis that might require frequent or intermittent antibiotic treatment


eligible ages (years): 18.0-70.0,  All  Ankylosing Spondylitis Active and severe ankylosing spondylitis Ankylosing spondylitis refractory to standard anti-rheumatic treatment Between 18 and 70 years of age  Prior exposure to any TNF-inhibitor, including etanercept DMARDs (other than hydroxychloroquine, methotrexate and sulphasalazine) within 4 weeks of study drug initiation Dose of NSAIDs changed within two weeks of study drug initiation


eligible ages (years): 18.0-70.0,  All  Rheumatoid Arthritis Diagnosis of RA Currently receiving an adequate dose of methotrexate (MTX) for treatment of RA Active RA at time of screening and baseline  Previous or current treatment with etanercept (ETN), other tumor necrosis factor-alpha inhibitors, or other biologic agents Concurrent treatment with a DMARD, other than MTX, at screening Receipt of any DMARD, other than MTX, within 3 months before screening


eligible ages (years): 1.5-19.0,  All  Juvenile Idiopathic Arthritis Fulfills International League Against Rheumatism (ILAR) for SJIA Duration of SJIA lasting at least 6 weeks since onset Active disease as defined by at least two joints with active disease Not currently receiving methotrexate OR if taking methotrexate, the dose has remained stable or has been discontinued for 4 weeks prior to screening Has never received certain biologics OR if previously received biologics, discontinued etanercept for at least 4 weeks prior to screening and discontinued infliximab or adalimumab for at least 8 weeks prior to screening Not currently receiving corticosteroids OR if taking oral corticosteroids, the dose has remained stable between 2 and 60 mg/day for at least 2 weeks prior to screening  Past treatment with anakinra, rilonacept, or other biologic IL-1 inhibitor Treatment with other disease-modifying antirheumatic drugs (DMARDs) including, but not limited to, azathioprine, sulfasalazine, cyclosporine, and thalidomide within 4 weeks of screening Treatment with leflunomide without cholestyramine washout at the end of therapy Treatment with cyclophosphamide within 3 months of study entry Treatment with tacrolimus or tocilizumab within 4 weeks of study entry Treatment with rituximab within 6 months of study entry Treatment with intravenous immunoglobulin (IVIG) within 4 weeks of screening Kidney disease AST or ALT levels more than two times the upper limit of normal Bilirubin levels higher than 1.5 mg/dl


eligible ages (years): 18.0-999.0,  All  Rheumatoid Arthritis Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) and in accordance with local guidelines Patients eligible to anti-TNF therapy Patients naïve to anti-TNFa drugs Patients with radiography (hands and feet) executed by 6 months before the baseline or at baseline according to modified Sharp Van der Hejde method [Sharp JT et al. 1985; Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form  Patients with tumors Patients already included in clinical trials


eligible ages (years): 50.0-999.0,  All  Polymyalgia Rheumatica Rheumatoid Arthritis Rheumatic Disease Patients signing Informed Consent  Patients less than 50 years old


eligible ages (years): 18.0-999.0,  All  Rheumatoid Arthritis adult patients >/= 18 years of age active moderate or severe rheumatoid arthritis of <10 years duration with inadequate response to methotrexate or anti-TNF on methotrexate treatment for at least 10 weeks, at least 8 weeks on stable dose patients receiving oral corticosteroids and/or NSAIDs should be at stable dose for 4 weeks  rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA functional class IV by ACR classification history of inflammatory joint disease other than RA previous treatment with cell-depleting therapies, abatacept or rituximab active current or history of recurrent infection, or any major episode of infection requiring hospitalization or treatment with iv antibiotics <4 weeks or oral antibiotics <2 weeks prior to screening


eligible ages (years): 0.0-999.0,  All  Polymyalgia Rheumatica clinical diagnosis of polymyalgia rheumatica  decompensated diabetes mellitus decompensated arterial hypertension


eligible ages (years): 18.0-999.0,  All  Abnormality Inflammation Rheumatism gp Suspects or affected by rheumatoid polyarthritis Morning articular Stiffness of at least 15 minutes Arthalgias or Arthritises of at least three joints(articulations), among which those of the hand Possible rheumatoid Presence of a factor(mailman) and\or Antibody anti peptides positive citrullinés Typical possible radiological Hurts on the standard clichés(pictures) of the reached(affected) joints(articulations) gp Affected by stiffening spondylitis with axial and peripheral infringement   Lumbago and steepness lumbar vertebra inflammatory. 2. Arthralgias and\or peripheral arthritises 3. Possible presence of an allèle HLA 4. Possible presence of a sacro-illite 5. Absence of the other rheumatic markers gp Affected by connectivity with anti-nuclear antibody positive and / or specific antibodies, suffering of polyarthralgias with or without arthritis gp Healthy control gp Presenting a degenerative osteoarthritis of the wrist traumatic comment, noticed radiologically, which will serve as not inflammatory control  Claustrophobia metallic foreign bodies pacemakers The pregnant women parturients or who breast-feed are excluded from the study


eligible ages (years): 18.0-999.0,  All  Rheumatoid Arthritis Signed, IRB-approved, written informed consent Subjects can be of either gender but must be more than 18 years old Subjects must fulfill the disease activity for RA and a DAS28 will be assessed at baseline and at 2 months after rituximab therapy Aim A Eligible subjects must meet for RA and have an inadequate response to MTX defined as DAS28 >5.1. They must have been on a steady dose of MTX (between 15 and 20 mg /week for a minimum of 8 weeks). Subjects must have evidence of knee synovitis on exam to enter the study Aim B Subjects must have demonstrated a response to a TNF antagonist as evidenced by a DAS score <2.8 or <4 tender and swollen joints. Flare will be defined as a DAS 28 >5.1 of more than 8 swollen and tender joints. Subjects must have evidence of knee synovitis to enter the study. Subjects will be off etanercept, infliximab or adalimumab for 4 weeks before starting BCDT. All subjects must also be on a stable dose of DMARD (MTX, leflunomide, azulfidine, hydroxychloroquine) for 8 weeks before entry into the study  Patients will be excluded for medical or other reasons at the discretion of the investigators. The reasons for the must be recorded, e.g. risk of non-compliance, vulnerability, medically unstable, etc Active systemic disorders or inflammatory conditions (i.e., chronic infection with hepatitis B, hepatitis C or HIV) other than the conditions being studied Patients with a plasma creatinine > 1.5 mg/dl Aim B Subjects with an allergy to corticosteroids will be excluded from the study Anyone answering yes to the following questions will be excluded Do you have a history of Cardiac (Heart) pacemaker or defibrillator? Cardiac (Heart) valve replacement or prosthesis? Aneurysm clips from brain surgery?


eligible ages (years): 18.0-999.0,  All  Recurrent Melanoma Stage IV Melanoma Patients with metastatic melanoma who have measurable disease ECOG PS 0 or 1 Adequate bone marrow function WBC >= 3,000 Hgb >= 9 Plt >= 100 Adequate hepatic function, defined by the following parameters Total bilirubin WNL unless associated with hepatobiliary metastases or Gilbert syndrome, then total bilirubin =< 2 x ULN Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN unless associated with hepatic metastases, then ALT and AST =< 5 x ULN Signed, written informed consent


eligible ages (years): 50.0-999.0,  All  Polymyalgia Rheumatica patients with PMR, diagnosed according to the of Bird et al  patients with arthritis patients with giant cell arteritis patients with Parkinson's disease patients with hypothyroidism patients with scapulohumeral periarthritis patients with fibromyalgia patients unable to cooperate


eligible ages (years): 18.0-49.0,  All  Spondylitis, Ankylosing Diagnosis of axial spondyloarthritis as defined by Assessments in Ankylosing Spondylitis (ASAS)criteria Active symptoms defined as Ankylosing Spondylitis Disease Activity Index{BASDAI) > or = 4 Axial symptoms of back pain with a less than favorable response to on steroidal anti inflammatory drugs at optimal dosage for greater than 4 weeks  Evidence of current or recent episode of uveitis Evidence of IBD flare within 6 months Previous treatment with an anti Tumor necrosis factor(TNF) Active tuberculosis Radiographic sacroiliitis grade 3-4 unilaterally or >= 2 bilaterally


eligible ages (years): 18.0-999.0,  All  Rheumatoid Arthritis Ankylosing Spondylitis Psoriatic Arthritis Patients aged ≥ 18 years for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis Patients must fulfill international and national guidelines for the use of a biological disease modifying antirheumatic drug in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (chest x-ray and interferon gamma release assay or purified protein derivative-skin test negative for tuberculosis). In addition one of the following must be fulfilled unsatisfactory disease modifying antirheumatic drug response defined as failure to treatment with at least two disease modifying antirheumatic drugs including Methotrexate in patients with rheumatoid arthritis or psoriatic arthritis unsatisfactory non steroidal antiinflammatory drug response in patients with ankylosing spondylitis or unsatisfactory response to prior biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis or ankylosing spondylitis  Patients who meet contraindications as outlined in the latest version of the Humira syringe® summary of product characteristics and Humira Pen® summary of product characteristics Patients participating in another study program or clinical trial Patients who have been treated with Humira before


eligible ages (years): 18.0-999.0,  All  Rheumatoid Arthritis Must have a documented diagnosis of Rheumatoid Arthritis (1987 American College of Rheumatology Criteria) with onset of signs/symptoms of disease ≥ 4 months of duration from randomization Must be receiving treatment on an outpatient basis Must have active disease despite current methotrexate treatment as defined below ≥ 6 swollen joints (66 swollen joint count) AND ≥ 6 tender joints (68 tender joint count) -. Must meet at least one of the four lab requirements below High Sensitivity C-Reactive Protein (hsCRP) ≥ 10 mg/L Erythrocyte Sedimentation Rate (ESR) > 28 mm after the first 1 hour Positive for Rheumatoid Factor (RF) Positive for Anti-cyclic Citrullinated Peptide (anti-CCP) antibodies  Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization Rheumatic autoimmune disease other than Rheumatoid Arthritis, including systemic lupus erythematosus, mixed connective tissue disease, scleroderma, polymyositis or significant systemic involvement secondary to Rheumatoid Arthritis (eg, vasculitis, pulmonary fibrosis or Felty syndrome). Sjögren syndrome secondary to Rheumatoid Arthritis is allowable Functional Class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis Prior history of, or current, inflammatory joint disease other than Rheumatoid Arthritis (eg, gout, reactive arthritis, psoriatic arthritis, ankylosing spondylitis, Lyme disease) Receiving treatment with Disease-modifying antirheumatic drugs (DMARDs) (other than methotrexate), including biologic Disease-modifying antirheumatic drugs (DMARDs)Previous use is only allowed after adequate washout prior to randomization Inadequate response to treatment with an anti-tumor necrosis factor (anti-TNF) agent. Patients who terminated previous anti-tumor necrosis factor (anti-TNF) treatment due to cost or safety reason, such as discomfort with the subcutaneous injections, may participate in this study after adequate washout Treatment with any investigational agent within four weeks (or five half-lives of the investigational drug, whichever is longer) of screening Previous treatment with any cell depleting therapies, including investigational agents Treatment with intravenous gamma globulin, plasmapheresis or Prosorba® column within 6 months of baseline Intra-articular or parenteral corticosteroids are not allowed within 6 weeks prior to randomization


eligible ages (years): 50.0-999.0,  All  Osteoarthritis Clinical diagnosis of primary osteoarthritis of the knee(s) Presently receiving prescribed oral or topical analgesics for a minimum duration of two weeks prior to enrollment  Arthritis other than primary osteoarthritis Treatment with disease-modifying antirheumatic drugs (DMARDS), methotrexate or biologics Subtotal or total joint replacement in the affected knee Chronic severe pain of other causes that in the opinion of the investigator may require long-term analgesia or confound the present study Currently enrolled in a clinical trial or who have participated in a clinical trial within the past 30 days


eligible ages (years): 18.0-999.0,  All  Axial Spondyloarthritis Male and female subjects aged 18 years and over at the time of consent to the study Diagnosis of SpA, as defined by the ASAS for axial SpA Axial involvement refractory to previous or current intake of NSAIDs, defined as at least 2 NSAIDs at maximum tolerated dose determined from past medical history taken for a duration of > 1 month (for both NSAIDs combined) before the Screening visit Active axial involvement defined by mini  Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial Subjects who have received any previous treatment with etanercept or other TNFα inhibitors or biologic agents Subjects with a known or expected allergy, contraindication, or hypersensitivity to etanercept or its excipients


eligible ages (years): 18.0-25.0,  All  Exercise Anaphylaxis Young healthy females Between 18-25 years old No on medication (this includes contraceptives)  Medication use (including oral contraceptives) Amenorrhoea High blood pressure Very active (>3 hours per week of organized physical activity)


eligible ages (years): 20.0-95.0,  All  Osteonecrosis Osteoarthritis Osteoarthritis of hip joint requiring total hip arthroplasty  Neurologic disorders affecting motor function of lower extremity foot and ankle disorders limiting ambulation of the patient Patients with bone metabolic disorders other than osteoporosis which prevents normal bone metabolism Multi-systemic inflammatory arthritis which debilitates patients other than hip joint


eligible ages (years): 50.0-999.0,  All  Polymyalgia Rheumatica (PMR) Disease Specific Patients must meet the following to be eligible for study entry Diagnosed with polymyalgia rheumatica and enrolled within one month of diagnosis Disease Specific  Patients will be excluded from the study based on the following Symptoms or diagnosis of temporal arteritis, including headache, jaw claudication, hyperesthesia of scalp, abnormal palpated temporal artery, visual disturbances, temporal artery biopsy positivity Concurrent rheumatoid arthritis Presence of rheumatoid factor and CCP Other inflammatory arthritis or other connective tissue diseases, such as but not limited to systemic lupus erythematosus, systemic sclerosis, vasculitis, polymyositis, dermatomyositis, mixed connective tissue disease Treatment of polymyalgia rheumatica with more than 20mg of daily prednisone or its equivalent at the time of screening Treatment with more than 30mg of daily prednisone or its equivalent since diagnosis. Treatment with 30mg of daily prednisone or its equivalent since diagnosis for more than 2 weeks More than 4 weeks of corticosteroid therapy prior to enrollment History of bowel perforation within the past five years Active diverticulitis


eligible ages (years): 18.0-50.0,  All  Polymyalgia Rheumatica PMR patients that after 2 years of corticosteroid treatment are not able to reduce the dose of prednisone below 5 mg/day or equivalent PMR patients that after 6 months of corticosteroid treatment are not able to reduce the dose of prednisone below 7,5 mg/day or equivalent PMR patients should fulfill the proposed by Chuang et al (8) Age ≥ of 50 years Development of bilateral moderately/severe aching and stiffness persisting for 1 month or more, involving two of the following areas: neck or torso, shoulders or proximal regions of the arms, and hips or proximal aspects of the thighs ESR ≥ 40 mm/h Complete clinical response to low-dose of steroids (prednisone or equivalent ≤ 20mg/day)  -Patients with biopsy-proven GCA or those with cranial symptoms or signs suggestive of GCA but without biopsy-proven arteritis Patients with clinical features suggestive of RA or other connective tissue disorders Chronic infections such as HIV, hepatitis B or C, active mycobacterial or fungal infections, etc Neoplasm or a history of malignancy in the preceding 5 years Patients with multiple sclerosis or other demilinizating disorders Patients with cytopenias: leukopenia (leukocytes ≤ 3.5x109/L.), thrombocytopenia (platelets ≤ 100x109/L.) and/or anemia (≤ 10 g./dl.) Patients with cardiac failure (functional class III / IV) Any other condition that contraindicates Infliximab therapy


eligible ages (years): 20.0-89.0,  All  Allergic Rhinitis Geographic Tongue rhinitis and non-rhinitis patients willing to complete the study no limitation of tongue movement  more than 90 years old or younger than 20 years old unable to complete the study


eligible ages (years): 18.0-999.0,  All  Adenocarcinoma Pancreas Histological documentation of primary adenocarcinoma of the pancreas Surgically eligible for tumor resection with curative intent Age> 18 years old ECOG PS 0 or 1 Adequate bone marrow function (WBC>3,000; Hgb>9; Plt>100) Adequate renal function (Cr<1.5ULN) Adequate hepatic function (total bilirubin WNL unless associated with hepatobiliary metastases or Gilbert syndrome, then total bilirubin <2x ULN; and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 x ULN Signed, written informed consent  Non ductal adenocarcinomas, neuroendocrine neoplasms, cystic tumors of the pancreas such as cystadenomas, cystadenocarcinomas and solid pseudopapillary neoplasms. In addition adenocarcinomas arising from duodenum, distal bile duct, and ampulla will also be excluded Patients with M1 disease Patients with any type of recurrent pancreatic adenocarcinoma Prior therapy such as chemotherapy or radiation therapy for pancreatic cancer Patients with a previous history of active malignancy within 5 years prior to study entry, except 1) in situ cervical carcinoma or 2) non-melanoma skin cancer Previous treatment with any other compound that targets CD40 Concurrent treatment with any anticancer agent outside of this protocol Prior allogeneic bone marrow transplant History of autoimmune disorder, including type 1 diabetes mellitus, pemphigus vulgaris, systemic mastocytosis, systemic lupus erythromatosis, dermatomyositis/polymyositis, rheumatoid arthritis, systemic sclerosis, Sjorgen's syndrome, vasculitis/arteritis, Behcet's syndrome, autoimmune thyroiditis, multiple sclerosis, or uveitis. Vitiligo is allowed History (within the previous year) of stroke or transient ischemic attack, unstable angina, myocardial infarction, congestive heart failure


eligible ages (years): 50.0-999.0,  All  Flu Common Cold First Men and women aged 50 + years It is accepted that the subjects can be treated for medical diseases It is also accepted that the subjects receiving daily medication such as diuretics and medication for Hypertension, hypercholesterolemia and blood glucose-lowering treatment, medicine that strengthens the heart, symptom-relieving medication for joint disease, etc Subjects may also use n-3 fatty acids (fish oil), as long as the fixed dosage  Subjects who have been treated with rose hip extracts or powder within 3 months before screening Subjects who have been treated with ginger, avocado / soy, large doses of vitamins (including vitamin C) or other known dietary supplements within 3 months before screening Subjects that have been deemed to be have a hard time collaboration Subjects who abuse narcotics Subjects who abuse alcohol Subjects with a current mental illness Subjects with known allergy to rose hips Subjects participating in another clinical trial, or have participated in another clinical trial within 3 months before this trial started


eligible ages (years): 5.0-15.0,  All  Rheumatic Heart Disease Schoolchildren in Southeast Nepal aged 5-15 years Written informed consent by the principal of the school Passive consent from the parents  No formal apply


eligible ages (years): 18.0-999.0,  All  Rheumatoid Arthritis The Test Group will be patients with rheumatoid arthritis, newly starting therapy with etanercept (Enbrel). for the exposed cohort subjects are Patients aged 18 years and over at the time of diagnosis Patients from the BSRBR with moderate RA as defined by a DAS28 (>3.2 and ≤5.1) Patients who have given informed consent for long term follow-up and access to all medical records Patients initiating (i.e. at leats one treatment) treatment with etanercept (Enbrel) for RA The Control Group Patients aged 18 years and over a the time of diagnosis Patients from the BSRBR with moderate RA as defined by a DAS28 (>3.2 and ≤5.1) Patients who have given informed consent for long term follow-up and access to all medical records; Patients are receiving at least one traditional DMARD and have never been prescribed a biologic agent  Per BSRBR registry since data is retropsectively being analyzed


eligible ages (years): 18.0-999.0,  All  Patient Harboring Glioblastoma That Will Undergo Surgery Patients harboring Glioblastoma Patient will undergo surgery  BMI > 30 Liver and Kidney Function so compromised that medication is prescribed


eligible ages (years): 18.0-80.0,  All  Systemic Sclerosis Systemic sclerosis fulfilling ACR or LeRoy's Active polyarthritis defined by > 6/53 tender joints and > 4/53 swollen joints Ongoing first line therapy by prednisone (max 10 mg/d) and (methotrexate, leflunomide, azathioprine or mycophenolate) Birth control if applicable  Overlap syndrome defined by clinical symptoms and positive specific auto-antibodies (anti-CCP, anti-SSA, anti-DNA DNA anti-Sm) (Rheumatoid factors and anti-RNP are not Past therapy with Rituximab Severe and uncontrolled disease with renal, liver or haematological (neutropenia < 1500 / mm3) failures, pulmonary (FVC < 50%) or cardiac insufficiencies (LVEF < 50%) Not stable corticosteroid therapy or cyclophosphamide use in the last 6 months Infectious risk : viral infections by B or C hepatitis or HIV, hypogammaglobulinemia (< 6 G/L), opportunistic infection or infection requiring IV antibiotics in the last 3 months Neoplastic solid tumor in the last 5 years Drug or alcool abuses Receiving patient or having received a biotherapy (anti-TNF, abatacept or tocilizumab) in the last 3 months (possible beyond 3 months)


eligible ages (years): 18.0-999.0,  All  Rheumatoid Arthritis A patient will be enrolled in this study if he/she fulfills ALL of the following Male or Female patients ≥ 18 years of age with diagnosis of RA Patient is eligible to start adalimumab therapy according to the local product label and prescription guidelines Patient is naïve to all biologics e.g. anti-cluster of differentiation 4 (anti-CD4) and anti-TNF treatments at the start of the study Patient has no history of inflammatory arthritis other than rheumatoid arthritis Patient has no history of lymphoma or leukemia or other malignancies Has negative result of tuberculosis (TB) screening test or is receiving TB prophylaxis as per local guidelines, Provided written Authorization to the investigator to use and/or disclose personal and/or health data, or Informed Consent if requested by the Local Regulations  Patients that are not diagnosed with rheumatoid arthritis as judged by the American College of Rheumatology Patient is currently diagnosed with any condition other than rheumatoid arthritis that may affect radiography progression Susceptibility to infections including TB, as judged by the investigator Patient is carrier of Hepatitis B virus Patient is a pregnant or lactating female at the time of screening


eligible ages (years): 50.0-999.0,  All  Polymyalgia Rheumatica Males or females, 50 years of age or older who provided written informed consent Females less than one year post-menopausal must have a negative serum or urine pregnancy test recorded prior to the first dose of study medication, be non-lactating, and willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner) Subjects newly diagnosed with polymyalgia rheumatica and previously untreated with glucocorticoids for PMR. The diagnosis of polymyalgia rheumatica must be confirmed by all of the following New onset bilateral shoulder pain or new onset bilateral shoulder and hip girdle pain PMR VAS score over the last 24 hours before the Screening Visit ≥ 50 (on a 0 scale) Morning stiffness duration of ≥ 45 min on the day before the Screening Visit Acute phase response shown by elevated C-reactive protein (CRP; ≥ 2 times ULN) Subjects willing and able to participate in all aspects of the study and comply with the use of study medication  Females who are pregnant (positive β-hCG test) or lactating Subjects with any contraindication/history of hypersensitivity to predniso(lo)ne or other ingredients Significant renal impairment (serume creatinine > 150 µmol/L) Significant hepatic impairment (ALT, AST and GGT > 2.5 ULN) Subjects suffering from another disease which requires glucocorticosteroid treatment. Topical glucocorticosteroids, e.g. intra-nasal or inhaled glucocorticosteroids are allowed but should be kept at a stable dose throughout the study Continued use of systemic glucocorticoids within 4 weeks prior to the Screening Visit Joint injections with glucocorticoids within 6 weeks prior to the Screening Visit Subjects who require treatment with non-permitted concomitant therapies Evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal or psychiatric disease at the time of screening, as determined by medical history, clinical laboratory tests, ECG results, and physical examination, that would place the subject at risk upon exposure to the study medication or that may confound the analysis and/or interpretation of the study results Active alcohol or drug abuse


eligible ages (years): 18.0-75.0,  All  Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis Patient 18-75 years of age, inclusive Patient qualifies for primary total knee arthroplasty based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis collagen disorders and/or avascular necrosis of the femoral condyle post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy moderate valgus, varus, or flexion deformities the salvage of previously failed surgical attempts that did not partial or total knee arthroplasty of the ipsilateral knee Patient has participated in a study-related Informed Consent process Patient is willing and able to complete scheduled study procedures and follow-up evaluations Independent of study participation, patient is a candidate for commercially available Persona fixed bearing knee components implanted in accordance with product labeling  Patient is currently participating in any other surgical intervention studies or pain management studies Previous history of infection in the affected joint and/or other local/systemic infection that may affect the prosthetic joint Insufficient bone stock on femoral or tibial surfaces Skeletal immaturity Neuropathic arthropathy Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb Stable, painless arthrodesis in a satisfactory functional position Severe instability secondary to the absence of collateral ligament integrity Rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin Patient has a known or suspected sensitivity or allergy to one or more of the implant materials


eligible ages (years): 5.0-17.0,  All  Acute Rheumatic Fever For the study subjects, diagnosis of ARF was made according to the Modified Jones (4) and appropriate treatment was started. Patients were divided into three groups by clinical findings. Group 1 included patients with only chorea, while patients with arthritis and carditis were involved in Group 2 and patients with only carditis were included in the Group 3. A group with only arthritis was not established since the patients with isolated arthritis are usually followed up at primary and secondary healthcare facilities rather than referring those patients to our tertiary healthcare center


eligible ages (years): 21.0-99.0,  All  Joint Pain Breast Cancer Taking an aromatase inhibitor as adjuvant treatment for State I, II, or II breast cancer for at least 4 weeks Experiencing more than mild joint pain/symptoms or older have permission from physician to engage in moderate intensity physical activity  Undergoing chemotherapy and/or radiation therapy at any time during the study period Scheduled for major surgery during the study period Presently engaged in high levels of physical activity on a daily basis Less than 21 years of age Unable to walk or engage in moderate intensity physical activity


eligible ages (years): 0.0-999.0,  All  Degenerative Joint Disease The following diagnostic for patient selection are to be used Patients will need to have a history of chronic pain (at least 3 months) refractory to conservative therapy with non-steroidal anti-inflammatory medications, muscle relaxants, diet modifications and splint therapy Patients will also need to have imaging findings (radiography or magnetic resonance imaging) that show mild to severe degenerative changes of the temporomandibular joint  will Patients with systemic disorders such as rheumatic diseases, hematologic diseases, active infections, immunosuppression Patients receiving therapy with anticoagulants


eligible ages (years): 18.0-75.0,  All  Rheumatoid Arthritis Age 18 Patients with Rheumatoid Arthritis undergoing primary total hip replacement surgery Satisfy American College of Rheumatology(ACR)/European League Against Rheumatism(EULAR) 2010 classification and/or the 1987 RA (see below) and be diagnosed with RA  Diagnosis of any other systemic rheumatic disease Diagnosis of or crystalline arthropathy Unable to understand or read English Unable to follow the study protocol in a reliable manner Age < 18 or >75


eligible ages (years): 5.0-999.0,  All  Rheumatic Heart Disease Clinical and echocardiographic signs of RHD using WHF  Congenital heart disease


eligible ages (years): 18.0-85.0,  All  Cardiovascular Diseases For the group 1 and 2 Men having an age ranging between 18 and 35 years Unhurt subject of any acute pathology for more than 7 days Consent signed by the subject  Subject presenting a known arterial high blood pressure (blood pressure > 140/90 mmHg) or any cardiovascular history Subject presenting a known renal insufficiency Subject presenting a known anaemia (Hb < 12g/dl) Subject presenting a known diabetes Subject presenting a cancer diagnosed less than 5 years previously or evolutionary cancer Subject presenting a chronic liver disease Subject presenting a connectivite: Rhumatoid polyarthritis Crohns disease Current tuberculosis Any medicinal treatment


eligible ages (years): 0.0-999.0,  All  Osteoarthritis of Hip Congenital Hip Dysplasia Avascular Necrosis Patients scheduled for primary, unilateral total hip replacement (THR) with no previous history of hip replacement and/or fracture surgery Patients with arthritis secondary Noninflammatory Degenerative Joint Diseases (NIDJD), including osteo/degenerative arthritis, congenital hip dysplasia, and avascular necrosis Patients who do not meet any of the  Patients with previous fusions, acute femoral neck fractures, above knee amputations, or previous total knee replacement Patients who had previously undergone an ipsilateral hemi resurfacing, total resurfacing, total bipolar, unipolar or total hip replacement device Patients with neuropathic joints Patients who required structural bone grafts Patients with an ipsilateral girdlestone Patients who otherwise met the study but for which appropriate clinical follow-up data is not available (i.e. patients deceased prior to 2-year follow-up, patients refused to return for follow-up)


eligible ages (years): 5.0-999.0,  All  Rheumatic Heart Disease Mitral Stenosis Cases Diagnosis of rheumatic heart disease based on one of World Heart Federation definite echocardiographic World Heart Federation borderline echocardiographic and history of acute rheumatic fever Mitral stenosis with valve area less than 2.0 cm2 Previous surgery for rheumatic heart disease  Age less than five years Inability to give consent New Controls Healthy individual living in a community where cases were identified Past medical history or systems suggestive of rheumatic heart disease, acute rheumatic fever or other valvular heart disease Age less than five years Inability to give consent


eligible ages (years): 5.0-17.0,  All  Juvenile Idiopathic Arthritis Diagnosis of JIA (ILAR classification) Age 5 to 17 years Ability to speak/read French or English; one caregiver per child will be recruited Presence of pain, defined as: pain reported by the child and/or caregiver, and/or joint tenderness and/or stress pain in at least 1 joint during physical examination performed by rheumatologist. Pain reported by the child/caregiver is not a prerequisite because some children develop behaviors and guarding postures to avoid pain Absence of anticipated change in treatment. If, during the study, a change in treatment is necessary, the change will be recorded but the child will not be withdrawn Stable dosages of medications and absence of intra-articular corticosteroid injections for 4 weeks prior to enrolment confirmed by child's rheumatologist  No current MT Systemic arthritis with quotidian fevers Acute infection Open skin lesion Fibromyalgia Sleep apnea Medications: anticoagulants, muscle relaxants, analgesic medications (acetaminophen allowed) Pregnancy


eligible ages (years): 18.0-50.0,  All  Patellofemoral Pain Syndrome Age between fifteen and thirty-five years Presenting unilateral PFPS with six months of evolution Presenting anterior or retro knee pain that presents itself when undergoing two or more of the following activities (squatting, running,kneeling, jumping,climbing stairs,physically active patients, with at least thirty minutes of physical activity at least three times per week.)  Patients with previous knee surgeries Chronic pain with more than one year of evolution Pregnancy or suspected pregnancy Application of intra-articular steroids in the three months prior to their evaluation Patients with meniscal injuries Ligament or intra-articular knee structures Degenerative diseases such as diabetes Rheumatoid arthritis OA of the knee, hip or ankle History of dislocation or subluxation of patella


eligible ages (years): 5.0-16.0,  All  Rheumatic Heart Disease Acute Rheumatic Fever Schoolchildren aged 5 to 15 years Written informed consent


eligible ages (years): 6.0-16.0,  All  Rheumatic Fever Rheumatic heart disease with recommended strep prophylaxis  less than one year from first diagnosis refusal to take the tablets


eligible ages (years): 18.0-999.0,  All  Arthritis Vasculitis Healthy volunteer or Recent diagnosis of rheumatoid arthritis within 1 month or New diagnosis of giant cell arteritis within 1 month or New diagnosis of anti-neutrophil cytoplasm antibody associated vasculitis within 1 month or Flare of anti-neutrophil cytoplasm antibody associated vasculitis within one month  Unable to provide written informed consent


eligible ages (years): 25.0-40.0,  All  Theca Lutein Cyst of Left Ovary Criteria:Sub-fertile women with confirmed diagnosis of pelvic endometriosis  women with Pelvic inflammatory disorders and other forms of benign cysts


eligible ages (years): 18.0-50.0,  All  Healthy Male and female healthy adults ages 18 to 50 years inclusive Good general health as determined by screening evaluation no greater than 42 days before the first immunization For women of childbearing age, use of adequate birth control from enrollment until 180 days after the last injection Written informed consent, after reading the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee  Presence of any febrile illness or any known or suspected acute illness on the day of any first immunization Any chronic illness, whether or not active treatment is required Any immunodeficiency (congenital or acquired) Any history of cardiac pathology (acquired or severe/persistent congenital) Any history of congenital malformation syndromes associated with congenital heart disease (syndrome complexes, e.g. VATER association; chromosomal disorders, e.g. Down's Syndrome; teratogenic agents, e.g. fetal alcohol syndrome; others, e.g. Noonan's) Any history of clinical manifestations of auto-immune or systemic diseases (inflammatory disorders, e.g. JRA, SLE, Kawasaki disease; inborn errors of metabolism, e.g. Fabry; connective tissue disorders, e.g. Marfan syndrome; neuromuscular disorders, e.g. Friedreich ataxia; endocrine-metabolic disorders, e.g. hypothyroidism; hematologic disorders, e.g. sickle cell anemia) Any history of acute rheumatic fever (ARF), post-streptococcal glomerulonephritis (PSGN), undiagnosed acute self-limiting polyarthritis (swelling, heat, redness or tenderness or pain and limitation of motion in >2 joints), or chorea (purposeless, involuntary rapid movements of the trunk and/or extremities) Any previous echocardiogram suggestive of cardiac pathology Any immediate family history (parents, siblings) of ARF, PSGN, self-limiting polyarthritis, chorea, or a collagen-vascular disease such as Lupus or Sjögren's syndrome Receipt of systemic glucocorticoids (a dose ≥ 20 mg/day prednisone or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within six months


eligible ages (years): 18.0-999.0,  All  Pancreatic Cancer Histological documentation of primary adenocarcinoma of the pancreas Surgically eligible for tumor resection with curative intent Age ≥18 years ECOG PS 0 or 1 Adequate bone marrow function (ANC ≥1,500; Hgb >9; Plt >100) Adequate renal function (Cr <1.5 ULN) Total bilirubin ≤1.5 x ULN; and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 x ULN (values post biliary stenting allowed for eligibility) Signed, written informed consent  Non ductal adenocarcinomas, neuroendocrine neoplasms, cystic tumors of the pancreas such as cystadenomas, cystadenocarcinomas and solid pseudopapillary neoplasms. In addition, adenocarcinomas arising from duodenum, distal bile duct, and ampulla will also be excluded Patients with M1 disease or a history of M1 disease Patients with any type of recurrent pancreatic adenocarcinoma Prior therapy such as chemotherapy or radiation therapy or anti-tumor experimental therapy for pancreatic cancer Previous treatment with any other compound that targets CD40 Concurrent treatment with any anticancer agent outside of this protocol Prior allogeneic bone marrow transplant History of autoimmune disorder, including type 1 diabetes mellitus, pemphigus vulgaris, systemic mastocytosis, systemic lupus erythromatosis, dermatomyositis/polymyositis, rheumatoid arthritis, systemic sclerosis, Sjörgen's syndrome, vasculitis/arteritis, Behcet's syndrome, autoimmune thyroiditis, multiple sclerosis, or uveitis,. (Vitiligo is allowed) History (within the previous year) of stroke or transient ischemic attack, unstable angina, myocardial infarction, congestive heart failure History of deep venous thrombosis or migratory thrombophlebitis (Trousseau)


eligible ages (years): 2.0-17.0,  All  Juvenile Idiopathic Arthritis Male or female aged 2 to <18 years. *IMPORTANT NOTE * Initial enrollment in the study will be limited to subjects ≥6 years of age and subjects weighing ≥15 kg. Following enrollment and PK analysis of subjects to <6 years of age with JIA in the ongoing Phase 1 PK study (A3921103), enrollment will be opened to this age group. The Sponsor will notify investigator sites when it is permissible to enroll subjects 2 to <6 years of age, as well as the corresponding dosage for this age group Must meet International League Against Rheumatism (ILAR) JIA diagnostic for one of the following categories with active disease for at least 6 weeks Extended oligoarthritis Polyarthritis (RF+) Polyarthritis (RF) Systemic JIA with active arthritis but without active systemic features in the prior 6 months and at the time of enrollment Psoriatic arthritis Enthesitis related arthritis. Subjects with polyarticular course JIA (ie, extended oligoarthritis, polyarthritis RF+, polyarthritis RF, systemic JIA with active arthritis but without active systemic features) must have a minimum of 5 active joints (an active joint is defined as a joint with swelling or, in the absence of swelling, limited range of motion accompanied by either pain or tenderness) at baseline to be eligible for study entry Subjects with psoriatic or enthesitis related arthritis must have a minimum of 3 active joints (an active joint is defined as a tender/painful and/or swollen joint) at baseline to be eligible for study entry Treatment with stable doses of Non Steroidal Anti inflammatory Drugs (NSAIDs), oral glucocorticoids (at a maximum dose of 0.2 mg of prednisone equivalent per kilogram per day or 10 mg per day for 2 weeks before baseline, whichever is lower), or methotrexate (10 mg and 20 mg per square meter of body surface area for 3 months before baseline) are permitted  Subjects with any of the following characteristics/conditions will not be included in the study Previous JIA treatment with tofacitinib Systemic JIA (sJIA) with active systemic features (including subjects with characteristic sJIA fever and rash or serositis within 6 months of enrollment) Persistent oligoarthritis Undifferentiated JIA Infections Latent or active tuberculosis (TB), or any history of TB Chronic infections Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within the 6 months prior to the first dose of study drug Any treated infections within 2 weeks of Baseline visit


eligible ages (years): 45.0-999.0,  All  Osteoarthritis, Knee Osteoarthritis, Hip years of age or older McMaster employee Sedentary job (stand or walk for <1/3 of work day) Able to safely climb two flights of stairs Hip pain Hip pain during internal rotation and hip flexion Knee pain Less than 30 minutes of morning stiffness in the knee Crepitus in the knee with active range of motion Bony enlargement around the knee  Any other forms of arthritis Osteoporosis-related fracture History of patellofemoral symptoms Active non-arthritic hip or knee disease Hip or knee surgery Use of cane or walking aid Unstable heart condition Neurological conditions Hip, knee or ankle injuries in past 3 months Physician-advised restriction to physical activity


eligible ages (years): 18.0-999.0,  All  Psoriatic Arthritis Must have a confirmed diagnosis of psoriatic arthritis (PsA) as determined by a rheumatologist according to ClASsification for Psoriatic Arthritis (CASPAR) Must be starting or any approved tumor necrosis factor alpha inhibitor (TNFi) (including TNFi biosimilars) as a first, second or third line of biologic disease-modifying antirheumatic drug (bDMARD) therapy for PsA at the time of enrollment into the observational study or within a maximum 1-month window after the baseline visit Must sign a participation agreement/informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements  Participant is starting or a TNFi therapy as fourth or further line of biologic treatment Participant is unwilling or unable to participate in long-term data collection Participant has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study or the first data collection time point Participant is currently enrolled in an interventional study


A 46-year-old woman presents  with a 9 month history of weight loss (20 lb), sweating, insomnia and diarrhea. She reports to have been eating more than normal and that her heart sometimes races for no reason. On physical examination her hands are warm and sweaty, her pulse is irregular at 110bpm and there is hyperreflexia and mild exophthalmia.

eligible ages (years): 18.0-60.0,  All  Heart Diseases Obesity Vascular Diseases Men and women, ages 18 to 60. Body weight was 130 to 180 percent of ideal body weight


eligible ages (years): 17.0-999.0,  All  Liver Cancer Histologically confirmed primary hepatocellular carcinoma (HCC) Completely resected disease with clear margins No residual disease by postoperative CT scan No metastatic disease Age and over Performance status Karnofsky 60-100% Life expectancy Not specified


eligible ages (years): 18.0-999.0,  All  Recurrent Thyroid Cancer Stage IVA Follicular Thyroid Cancer Stage IVA Papillary Thyroid Cancer Stage IVB Follicular Thyroid Cancer Stage IVB Papillary Thyroid Cancer Stage IVC Follicular Thyroid Cancer Stage IVC Papillary Thyroid Cancer Histologically confirmed papillary thyroid or follicular thyroid carcinoma Differentiated disease Metastatic disease documented by ultrasound, computed tomography (CT) scan (without iodinated contrast), or MRI All metastatic disease foci =< 10 mm in all dimensions Must have been treated with total or near-total thyroidectomy AND at least 1 course of iodine I 131 (131I)(>=29.9 mCi) OR demonstrated negative uptake on a postoperative low-dose131I scan Must have undergone whole body 131I scan 1-3 days after administration of =< 5.5 mCi of 131I demonstrating no visible iodine uptake within the lesions unless demonstrated negative uptake on a postoperative low-dose131I scan within the past 12 weeks Must have 24-hour urine iodine excretion =< 500 mcg within 1 week of 131I scan Must be receiving thyroid hormone therapy AND have thyroid-stimulating hormone level =< 0.5 mU/L No known brain metastases Performance status


eligible ages (years): 18.0-999.0,  All  Thyroid Neoplasms Total or near total thyroidectomy performed for papillary or follicular thyroid cancer R0-1 resection, no macroscopic cancer left behind at surgery Physically and emotionally able to undergo radioiodine treatment A written informed consent  Pregnancy Physical or psychiatric illness that may deteriorate during the isolation period required by radioiodine therapy


eligible ages (years): 18.0-999.0,  All  Benign Nontoxic and Toxic Goiter Graves' Disease Healthy volunteers with an intact thyroid gland Patients with nontoxic/subtoxic nodular goiter confirmed by ultrasonography Patients with toxic nodular goiter Patients with Graves' disease  Treatment with drugs that alter thyroid function or size (the last 3 months prior to inclusion) Prior 131I treatment Alcohol, medicine or drug abuse Pregnancy or lactation No safe contraception Participation in another clinical trial Allergic reaction towards rhTSH Fine needle biopsy without valid diagnostic for benign disease Suspicion of malignancy, increased ionized serum calcium and/or serum calcitonin Incontinence


eligible ages (years): 18.0-999.0,  All  Graves´ Disease Thyroid Associated Ophthalmopathy Graves´ disease Adequate anticonception in women  Performance status >2 Previous rituximab treatment Immunosuppressive treatment Serious concomitant disease Active infections Pregnancy / breast feeding


eligible ages (years): 18.0-85.0,  All  Toxic Nodular Goitre Graves' Disease Hyperthyroid patients going to be treated with radioiodine either due to recurrent Graves' disease or toxic nodular goiter  Age < 18 yrs Allergy to anti-thyroid drugs Substernal or large (> 100ml) goiter Severe endocrine ophthalmopathy Pregnancy or lactation Suspicion of thyroid malignancy Unsafe contra-conception Physical or mental condition that hinders corporation


eligible ages (years): 18.0-85.0,  All  Toxic Nodular Goitre Graves Disease Hyperthyroid patients going to be treated with radioiodine either due to recurrent Graves’ disease or toxic nodular goiter  Age < 18 yrs Allergy to anti-thyroid drugs Substernal or large (> 100ml) goiter Severe endocrine ophthalmopathy Pregnancy or lactation Suspicion of thyroid malignancy Unsafe contraconception Physical or mental condition that hinders corporation


eligible ages (years): 18.0-40.0,  All  Obesity healthy males Normal weigh, e.i. BMI between 18,5-25 kg/m2 age 18-40 years  donation of blood 3 monhts prior or during the study gastrointestinal disorders, diabetes, hypertension, hyperlipidemia, chronic infectious disease smoking consumption of more than 21 alcoholic drinks/week elite athletes on mediation diet supplements


eligible ages (years): 40.0-65.0,  All  Obesity BMI greater than 30 African American 46 years old  bariatric surgery within the previous 5 years


eligible ages (years): 21.0-60.0,  All  Graves Ophthalmopathy Confirmed TED (as defined by Bartley and Gorman19) Eyelid retraction (upper eyelid margin at or above the superior corneoscleral limbus in primary gaze without frontalis muscle contraction) in association with any one of the following Thyroid dysfunction or abnormal regulation (increased serum thyroxine or triiodothyronine level, decreased serum thyroid stimulating hormone level, absence of thyroid radioiodine uptake suppression after administration of triiodothyronine, or the presence of thyroid stimulating immunoglobulins in serum) Exophthalmos (Hertel measurement of at least 20mm) Extraocular muscle involvement (restrictive myopathy or objective evidence of enlarged muscles) Optic nerve dysfunction (abnormal visual acuity, colour vision, pupillary reaction or perimetry not attributable to other causes) Thyroid dysfunction or abnormal regulation in association with any one of the following -Exophthalmos Extraocular muscle involvement Optic nerve dysfunction  Previous treatment for TED Oral steroids (e.g. immunosuppressive dose) for last 3 months, radiotherapy Intravenous pulsed steroid or methrotrexate therapy Medically unfit to receive I/V high-dose pulsed methylprednisolone or methotrexate History of cardiac arrthymias, recent acute myocardial infarction History of seizure History of acute bleeding peptic ulcer History of pulmonary tuberculosis, Hepatitis B carrier, Hepatitis C positivity, HIV Uncontrolled diabetes or hypertension (to be eligible for the trial, random blood glucose must be < 11.1 mmol/L and blood pressure must be 140/90 or lower#. If above these limits, patients can be treated and reviewed at 2 weeks for enrolment when are met provided the patient does not have optic neuropathy)


eligible ages (years): 18.0-85.0,  All  Aging Balance Sleep Males and females Aged 18 to 35, or 60 to 85 Lived at Denver altitude or higher for at least one year Stable treated diseases: thyroid dysfunction (including hypothyroidism and hyperthyroidism), hypertension, hypercholesterolemia, urinary incontinence, prostate enlargement, gastroesophageal reflux disease, irritable bowel syndrome  Aged 36 to 59, under 18, or over 85 BMI less than 18.6 or greater than 30 kg/m2, women below 95 pounds regardless of BMI Sleep duration is less than 5 or more than 9 hours Sensitivity to sleeping medications Night work in the preceding 6 months Transmeridian travel (across more than 2 time zones) in the last 1 month Bone mineral density DXA T-score of less than -1.75 Orthostatic intolerance Prior history of falls in past year Prior history of injurious fall in past 5 years


eligible ages (years): 0.0-999.0,  All  Thyroid Neoplasms Thyroid Nodules Graves Disease Goiter Patients underwent thyroidectomy in Srinagarind hospital, Khonkaen University  Patients with cervical lymph nodes metastases requiring neck dissection Patients that tissue pathology shown anaplastic carcinoma Patients with clinical or laboratory indicators of coagulation disorders


eligible ages (years): 18.0-999.0,  All  Carcinoma, Islet Cell Carcinoma, Pancreas Well-differentiated advanced/metastatic pancreatic islet cell tumor Tumor has shown progression within the past year  Current treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or investigational anticancer agent other than somatostatin analogues Prior treatment with any tyrosine kinase inhibitors or anti-VEGF[Vascular endothelial growth factor] angiogenic inhibitors Prior treatment with non-VEGF-targeted angiogenic inhibitors is permitted


eligible ages (years): 14.0-61.0,  All  Graves Disease Graves disease  Anticoagulant usage Previous thyroid operation Refused to participate in this study


eligible ages (years): 18.0-75.0,  All  Subclinical Hypothyroidism Hyperthyroidism Thyroid Dysfunction patients with subclinical hypothyroidism or hyperthyroidism patients with thyroid nodules and normal thyroid function  patients who are taking thyroxine, antithyroid drugs, lithium or amiodarone patients who had thyroid surgery or radioiodine therapy patients with NYHA class 3 or 4 heart failure


eligible ages (years): 0.0-999.0,  All  Thyroid Cancer histologically confirmed differentiated thyroid cancer status after total thyroidectomy status after subsequent high-dose radioiodine treatment regular follow-up by a board-certified dentist a minimum follow-up of 1 year after radioiodine therapy  anaplastic thyroid cancer


eligible ages (years): 18.0-50.0,  All  Obesity healthy meals BMI 24-31 kg/m2 age between 18-50 years hemoglobin >8 mmol/L  donation of blood 6 months before and under the study milk allergy, diabetes, hypertension, hyperlipidemia, cronic infectious disease use of dietary supplements 3 months before and under the study smoking elite athletes use of medication


eligible ages (years): 0.0-999.0,  All  Hyperthyroidism Cardiovascular Diseases Atrial Fibrillation Patients: Radioiodine treatment for hyperthyroidism given in the Tampere University Hospital between January 1969 and June 2002 Controls: age and gender-matched control subject identified for each patient from the Population Register Centre. The control subject had to be alive at the time when the patient received the first RAI treatment


eligible ages (years): 20.0-999.0,  All  Neoplasms, Gastrointestinal Tract Specific Information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on the investigational product that may impact subject is provided in the Investigator's Brochure (IB) Pilot Part Subjects eligible for enrollment in the Pilot Part of the study must meet all of the following Signed informed consent Male or female; ≥ 20 years (at the time of giving consent) Any histologically or cytologically confirmed gastric carcinoma independent of tumor ErbB2 status Subjects who have received one prior regimen for gastric carcinoma and developed disease progression or recurrence. The regimen must have contained 5-fluoropyrimidine and/or cisplatin Left ventricular ejection fraction (LVEF) within institutional range of normal as measured by echocardiogram (ECHO). Multigated acquisition (MUGA) scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive (LVEF of ≥50% required if normal range of LVEF is not provided by institution) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 Able to swallow and retain oral medication Women and men with potential to have children must be willing to practice acceptable methods of birth control during the study  Subjects meeting any of the following must not be enrolled in the study Pregnant or lactating female at anytime during the study Planned concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, hormonal therapy) while taking investigational treatment Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities greater than grade 2) Peripheral neuropathy of Grade 2 or greater Malabsorption syndrome, disease significantly affecting gastrointestinal function. Subjects with ulcerative colitis and Crohn's disease are also excluded History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety Life threatening infection Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent


eligible ages (years): 18.0-999.0,  All  Advanced Cancer Anorexia Weight Loss Insomnia Advanced cancer patients seen in outpatient clinics or inpatient units at MD Anderson Cancer Center, with presence of anorexia for at least one month, and accompanied by weight loss of > 5 % of pre-illness body weight in the last 6 months. Anorexia on the day of enrollment (day 0 +/-3) must be > 4/10 on ESAS Patients > 18 years of age Karnofsky Performance score of > 40 at time of into study Ability to provide informed consent and comply with study procedures Ability and willingness to return to engage in telephone follow-up by research nurse on days 2 (+/ days), 8 (+/ days), 16 ( +/ days), and 22 (+/ days) and return to outpatient clinic for evaluation on days 15 (+/ days), and 29 (+/  Patients who have known dementia or delirium at time of enrollment as determined by a physician Known hypersensitivity to any ingredient of Mirtazapine Inability to maintain oral intake over the course of the study, such as with mechanical obstruction of the alimentary tract or intractable vomiting Ongoing use of tube feeding or parenteral nutrition Current use of corticosteroids (with the exception of scheduled doses during time of chemotherapy), dronabinol, testosterone and progesterone derivatives such as megestrol acetate, or in the preceding 1 week prior to study enrollment Pregnancy or lactation or unwillingness to use contraceptives A score of 11 or more, in each subscale of the Hospital Anxiety and Depression scale (HADS) indicating clinical depression or anxiety. Those with HADS scores of > 11 at baseline indicating moderate or severe depression will be excluded from the study and will be referred for appropriate follow up by counselor and psychiatry evaluation Patients on chronic use of benzodiazepines are excluded


eligible ages (years): 2.0-999.0,  All  Graves' Disease Graves' disease patients


eligible ages (years): 18.0-65.0,  All  Stroke Immobilization Myofacial Pain Hyperthyroid Myopathy Normals Healthy individuals Stroke a first stroke (i.e., a unilateral, ischemic hemispheric stroke) within the previous one to two months, ability to cooperate and follow simple commands, and gastrocsoleous strength in the affected lower extremity of between trace and 50% of normal Immobilization immobilized in a cast (typically 6 weeks) following sugical repair of a severe Achilles tendon tear or rupture, ankle injury or plantar fascial pain Myofascial Pain history of pain in trapezius confirmed by clincal examination. The examiner will perform snapping palpation over the MFTP. If a localized, transient contraction is observed, the response is considered to be positive and the subject will be considered eligible for entry into the study Hyperthyroid Myopathy clinical assessment in combination with a serum hormone profile of increased Free Thyroxine (FT4) and Triiodothyronine (T3) in the face of suppressed levels of Thyroid Stimulating Hormone (TSH)


eligible ages (years): 18.0-75.0,  All  Dyslipidemia Signed informed consent Males or females aged 18 to 75 years. Female patients must be non-fertile. To be considered as non-fertile, females must fulfil the following Non-nursing and non-pregnant 12 months prior to enrolment Not of child bearing potential ie, either documented irreversible surgically sterile (bilateral oophorectomy or hysterectomy is acceptable, but not tubal ligation) or post-menopausal. Post-menopausal is defined as serum follicle-stimulating hormone (FSH) levels in the post-menopausal range combined with amenorrhea for more than 1 year in a woman above 50 years of age, or amenorrhea for more than 2 years below 50 years of age Patients with hypercholesterolemia treated with stable doses of the below listed lipid lowering medication for at least 3 months prior to randomization Atorvastatin not more than 20 mg/day or Simvastatin not more than 40 mg/day LDL-cholesterol > 3.0 mmol/L (Week -1) Subject able and willing to comply with all study requirements At randomization, diet as instructed by the investigator during the last 4 weeks prior to randomization and willingness to follow these instructions throughout the study  Cholesterol lowering agents other than the defined statins History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the investigator Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product as judged by the investigator Chronic (> 3 months) pain condition requiring daily medication with pain killers Glycosylated haemoglobin (HbA1c) > 7.0% Diabetes requiring medication other than metformin Clinically abnormal physical findings and laboratory values as judged by the investigator and abnormal resting ECG, eg, QTc interval > 450 msec Body Mass Index of ≥ 40 kg/m2 Resent history (< 3 month) of stroke or transient ischemic attacks History of seizure disorder, except febrile convulsions


eligible ages (years): 18.0-999.0,  All  Turner Syndrome Turner syndrome verified by karyotyping  untreated hypothyroidism or hyperthyroidism present or past malignant diseases clinical liver disease treatment with drugs known to interfere with bone metabolism (e.g. glucocorticoids)


eligible ages (years): 20.0-60.0,  All  Graves Disease Patients with newly diagnosed hyperthyroid Graves' disease  If the patient had been treated previously diabetes, kidney, or liver disease


eligible ages (years): 18.0-60.0,  All  Electric Stimulation Therapy Obesity Weight Loss Eating BMI greater than or equal to 30 kg/m(2) Age 18-60 years. Women who are post-menopausal will be excluded from the study due to changes in their metabolism that could affect weight loss. We will set the cutoff at age 60 so that the age difference between the men and women is not too great for analysis purposes. Minors under the age of 18 will be excluded because the time requirements of the study are such that they would interfere with school schedules. Additionally, while the risks of TDCS are minimal, there haven t been studies showing how TDCS might affect the growing brain Healthy, as determined by medical history, physical examination, and laboratory tests Right-handedness (because the treatment will be given to the left dorsolateral prefrontal cortex and the evidence accumulated in this region was only in right-handed individuals) Weight stable (plus or minus 5 percent) for last 3 months  Weight less than 350 lbs, as this is the weight limit of the DXA machine Type 2 diabetes (according to the World Health Organization diagnostic criteria) Endocrine disorders (Cushing s disease, pituitary disorders, and hypo and hyperthyroidism) Chronic pulmonary disorders, including chronic obstructive pulmonary disease that would limit ability to follow the protocol (investigator judgment) and obstructive sleep apnea syndrome; only subjects with mild or exercise-induced asthma on no medications or on beta-adrenergic agonists only (such as albuterol) will be allowed to enter the study (provided use of these agents is not required for 1 week before study entry) Cardiovascular diseases (coronary heart disease, heart failure, arrhythmias, and peripheral artery disease) Hypertension (blood pressure measurement higher than 140/90 mmHg on 2 or more occasions or use of anti-hypertensive medications) Diagnosed gastrointestinal diseases, including inflammatory bowel diseases (e.g. Crohn s disease and ulcerative colitis), malabsorption syndromes (e.g. celiac disease), gastric ulcer (active); only subjects with gastro-esophageal reflux will be allowed to enter the study Liver disease (cirrhosis, active hepatitis B or C, and AST or ALT greater than or equal to 1.5 times normal) Renal disease (serum creatinine concentrations greater than or equal to 1.5 mg/dl and/or overt proteinuria)


eligible ages (years): 18.0-85.0,  All  Healthy Body mass index (BMI) < 30 kg/m2 Age 18-45 yr; or Age 65-85 yr  Those taking medications known to affect substrate metabolism or medications that may confound the findings from our study (synthetic steroids, glucocorticoids etc.) Those with evidence of significant organ system dysfunction (e.g. diabetes mellitis, cirrhosis, hypo or hyperthyroidism; hypertension) Body mass index > 30 kg/m2 Age <18 yr, 45-65 yr or > 85 yr Those performing >1.5h of exercise/wk


eligible ages (years): 18.0-999.0,  All  Graves Disease Hyperthyroidism Graves hyperthyroidism in remission after ATD  Age < 18, severe concomitant disease


eligible ages (years): 18.0-85.0,  All  Helicobacter Pylori Infected Patients Thyroid Cancer Patients Hyperthyroidism Adult patients between the ages of 18 and 80 Patients with diagnosed thyroid disease referred for thyroid scan or treatment with radioactive iodine (131I) Patients who provide informed consent  Patients without diagnosed thyroid disease Patients who are pregnant or breast feeding Patients who have received previous treatment for H. pylori infection Patients taking proton pump inhibitors Patients with recent or current use of antibiotics Patients allergic to iodine (131I)


eligible ages (years): 18.0-80.0,  All  Atrial Fibrillation Heart Failure Age ≥ 18 years, < 80years NYHA II-IV symptoms Impairment of left ventricular systolic function (left ventricular ejection fraction estimated as ≤ 35% by radionuclide ventriculography) Documented AF lasting for at least 7 days (persistent or permanent AF)  CRT or ICD device implanted in the previous 6 months AV nodal ablation within previous 3 months Prior AV nodal ablation or complete heart block with a single chamber pacemaker Contraindication to anticoagulation Persistent thrombus in the left atrium despite anticoagulation Active malignancy Cerebrovascular accident within the previous 6 months Reversible causes of AF including thyroid disorders, alcohol, recent surgery Reversible causes of heart failure including acute myocarditis or alcohol Cardiac events including myocardial infarction (MI), percutaneous coronary intervention (PCI), valve or coronary bypass surgery within the previous 3 months


eligible ages (years): 18.0-999.0,  All  Graves Disease Hyperthyroidism Adult patients with a clinical diagnosis of Graves Disease Patients who have selected surgical resection as treatment of their Graves Disease Prior use of anti thyroid medication so that patient is clinically and biochemically euthyroid  Patients deemed unfit for surgery by operating surgeon or anesthesist Patients who are clinically hyperthyroid or have T3 or T4 levels 2X the upper limit of normal


eligible ages (years): 18.0-65.0,  All  Goiter Criterion a bilateral non-toxic multinodular goiter with normal appearing on ultrasound of the neck posterior aspects of both thyroid lobes  multinodular goiter involving posterior aspect/s of thyroid lobe/s suspicion of thyroid cancer previous thyroid surgery thyroiditis subclinical or clinically overt hypothyroidism or hyperthyroidism pregnancy or lactation age < 18 years or > 65 years ASA 4 grade (American Society of Anesthesiology) inability to comply with the follow-up protocol


eligible ages (years): 18.0-999.0,  All  Thyroid Cancer for patient participants Individuals with papillary thyroid carcinoma who have had complete resection of their thyroid at surgery (total or near-total thyroidectomy, or hemi [subtotal] with completion thyroidectomy)on or after September 1, 2009 Age at time of first thyroid cancer surgery must be at least 18 years or older The papillary thyroid cancer TNM pathologic stage must be pT1 or pT2, N0 (or Nx), M0 (or Mx) (TNM stage, AJCC VI) (ie. primary tumor size 1-4 cm, no known positive lymph nodes at the time of primary surgery, no extension of the tumor outside the thyroid, no venous or lymphatic invasion, and no known distant metastases at primary surgery, with no tall cell features, as per surgical pathology report) Must be able to communicate in spoken and written English Must be able to use a computer Must be able to provide informed consent on one's own (without any need for translation)  for patient participants Participants not meeting Concurrent diagnosis of medullary or anaplastic or poorly differentiated thyroid cancer or thyroid lymphoma Prior radioactive treatment for thyroid cancer Individuals who have been taken off their thyroid hormone for testing or treatment, will not be eligible for the study while off this medication Individuals who are unwilling for investigators to confirm their pathologic stage of disease through review of pathology report(s) will be ineligible for the study for the physician feedback component of this study Physicians and surgeons caring for thyroid cancer patients, in active practice at University Health Network in Toronto, Ontario, Canada


eligible ages (years): 18.0-85.0,  All  Multinodular Goitre Grave's Disease Thyroid Nodule multinodular goiter Grave's disease thyroid nodule  thyroid carcinoma reoperative surgery


eligible ages (years): 18.0-999.0,  All  Thyroid Neoplasm Advanced/poorly differentiated thyroid cancers of follicular cell origin that have no uptake (less than 1%) on radioiodine scan or are unresponsive to radioiodine therapy. Unresponsiveness to radioiodine therapy is defined as a patient s thyroglobulin not falling to less than 2ng/ml within 6 months after previous radioiodine ablative treatment Extensive (invasive) loco-regional tumor mass and/or metastatic spread, rendering patient inoperable Thyroglobulin (Tg) levels greater than or equal to 100 ng/ml in the absence of Tg antibodies. Patients who are Tg-antibody (Tg-Ab) positive may be included despite a lower Tg level if they have detectable disease on cross sectional imaging. (The presence of Tg-Ab may lead to falsely low Tg levels and therefore render the Tg a less sensitive marker of disease. However, Tg-Ab has been shown to also act as a tumor marker, and will be used as an endpoint for the study in patients who are Tg-Ab positive.) Within 18 months of enrollment, patients must have had an RAI scan, showing no or therapeutically insignificant RAI uptake (less than or equal to 1%) Initial therapy must have included total/near-total thyroidectomy and RAI ablation therapy Patients must have had no chemotherapy, radiotherapy, or biologic therapy for their malignancy in the month prior to treatment and must have recovered from all side effects of therapeutic and diagnostic interventions Greater than or equal to 18 years of age Must be able to understand and sign the Informed Consent Document Clinical performance status of ECOG less than or equal to 1 Life expectancy of greater than three months  Allergy to valproic acid Current coexisting malignancy other than basal cell carcinoma Women of child-bearing potential who are pregnant or breastfeeding Valproic acid is a known teratogen, causing primary neural tube defects, facial abnormalities, and skeletal malformation; therefore pregnant women will be excluded. Additionally, patients that become pregnant while on study protocol will be discontinued immediately Active systemic infections, coagulation disorders or other major medical illnesses Patients taking tolbutamide, warfarin, zidovudine, benzodiazapines, clonazepam, diazepam Seizure disorder


eligible ages (years): 16.0-60.0,  All  Graves' Disease Graves' disease patients. Healthy people  Pregnancy. <16 years old or > 60 years old


eligible ages (years): 8.0-90.0,  All  Hypothyroidism Exophthalmos a typical clinical symptoms of Graves disease, diffuse goiter, eye signs (including exophthalmos), thyroid function (FT3, FT4, rTSH) and thyroid autoantibodies and imaging examinations to confirmed  treatment contraindications, those who have not signed the informed consent, failure to complete treatment and follow-up estimates of patients and patients not suitable for radionuclide therapy


eligible ages (years): 15.0-85.0,  All  Thyrotoxicosis Peak Systolic Velocity of Superior Thyroid Artery Thyroiditis Graves Disease newly diagnosed without taking any antithyroid drug or beta receptor blocker with TSH level below the lower limits of reference range is willing to be enrolled  unwilling taking antithyroid drug or beta receptor blocker taking foods or medicine rich in iodine in 8 weeks women with pregnant or lactation


eligible ages (years): 18.0-55.0,  All  QoL Before and After 9 Month of Medical Treatment of Graves´Thyrotoxicosis Potential Effect of Selenium New diagnose of autoimmune thyrotoxicosis biochemically proven with increased thyroxin low TSH and elevated TRAb/or positive scintigraphy Age 18 Willing to participate -  No previous head trauma No difficulties with swedish language No medication which could affective neuropsychological testing No planned or ongoing pregnancies Normal intellectual capacity No severe ophthalmopathy, or other severe disease


eligible ages (years): 20.0-64.0,  All  Irritable Bowel Syndrome Patients meeting the Rome III Diagnostic Loose (mushy) or watery stools within the last 3 months Abdominal discomfort and/or pain during their non-menstrual period  Patients with a history of surgical resection of the stomach, small intestine or large intestine Patients with a history or current diagnosis of inflammatory bowel disease (Crohn's disease or colitis ulcerative) Patients with a history or current diagnosis of colitis ischemic Patients with a current diagnosis of enteritis infectious Patients with a current diagnosis of hyperthyroidism or hypothyroidism Patients who are currently participating in another clinical trial (including a post-marketing clinical study) or those who participated in another clinical trial (including a post-marketing clinical study) within 12 weeks before the study Patients with a history or current diagnosis of malignant tumor Patients with a history of abuse of drugs or alcohol within 1 year or those who are currently abusing them


eligible ages (years): 18.0-40.0,  All  Healthy Middle-aged Subjects Age Range Was 18 to 31 Years Caucasian Whites Males and Females healthy middle-aged subjects  volunteers with systemic or ocular diseases


eligible ages (years): 40.0-69.0,  All  Overweight and Obese by BMI women aged 40-69 overweight or Class I & II obese (BMI 28 to 39.9)or BMI 40 to 45 with physician clearance state a commitment to losing weight speak and read English able to communicate over the telephone able to use a computer with minimal assistance and complete electronic forms and surveys have access to and are able to access the Internet commitment to access the website as required by the research intervention including weekly self-reporting of calories and fat grams, weekly self-reporting of physical activity, pedometer steps, and body weight, and weekly (or more often) participation in other website components as determined by group to which randomized and phase of intervention have or are willing to obtain an email account have access to a DVD player  diagnosed with Type 1 diabetes diagnosed with Type 2 diabetes and require insulin ≥ 10% weight loss in last six months enrolled in a weight loss management program enrolled in a formal program of cardiac rehabilitation or undergoing physical rehabilitation taking medications that affect weight loss or weight gain other physical or medical restrictions that would preclude following the minimum recommendations for moderate physical activity and healthy eating


eligible ages (years): 18.0-85.0,  All  Thyroid Nodule Goiter Thyroiditis Graves Disease The patient must have given his/her informed and signed consent The patient must be insured or beneficiary of a health insurance plan The patient is available for 12 months of follow-up The patient is a candidate for total thyroidectomy because of a nodular pathology, a diffuse goiter, thyroiditis, or Basedow's disease Patient has calcitoninemia < 9 ng/pl Patient has normal calcemia Patient has PTH level between 5 ng/l and 75 ng/l The subject has a normal laryngeal mobility  The patient is participating in another study The patient is in an period determined by a previous study The patient is under judicial protection, under tutorship or curatorship The patient refuses to sign the consent It is impossible to correctly inform the patient The patient is pregnant The patient is breastfeeding The patient is not available for 12 months of follow-up Subject has a preoperative diagnosis of cancer on fine needle aspiration biopsy of the thyroid or cervical lymph node Lymph node metastasis strongly suspected clinically and/or sonographically


eligible ages (years): 18.0-999.0,  All  Graves Ophthalmopathy Clinical diagnosis of Graves Orbitopathy Clinical activity score higher than 2 Must be able to swallow tablets  sight-threatening Graves Orbitopathy Diplopia in primary gaze Macrolide allergy or intolerance


eligible ages (years): 2.0-16.0,  All  Paediatric Thyrotoxicosis All patients with thyrotoxicosis aged between 2 and 16 years at the time of diagnosis. Thyrotoxicosis will be diagnosed by the paediatrician on the basis of the clinical picture and the biochemistry (suppressed TSH with high thyroid hormone levels) Child has consented/assented or consent via parent/guardian has been gained prior to any study specific procedures  Known toxic adenoma / toxic hyperplasia (germline activating TSHR mutation) McCune Albright Syndrome Previous episodes of Thyrotoxicosis Known allergic response to any of the study medication or ingredients as per SmPC Previous participation in this study


eligible ages (years): 23.0-45.0,  All  Pregnancy Complicated by Hyperthyroidism Hypothyroidism in Pregnancy Autoimmune hyper or hypothyroidism, diagnosed by an endocrinologist, treated, based on clinical and laboratory tests and ultrasound thyroid examination Patients were included if they were seen by gynecologist at Clinic for Gynecology up until 20th week of gestation and not later healthy pregnant women in control group were directed for cordocentesis due to age  Any other chronic diseases


eligible ages (years): 18.0-999.0,  All  Papillary Thyroid Carcinoma Histologically confirmed papillary thyroid carcinoma, including its variants, such as tall cell PTC or poorly differentiated thyroid carcinoma, that is metastatic or unresectable AND harbors a BRAF V600E mutation Evaluable disease, as defined by at least one lesion that can be accurately measured in at least one dimension on CT scan or ultrasound, if present in the neck Radioiodine-refractory disease Life expectancy > 6 months Able to swallow and retain oral medication Normal organ and marrow function  Pregnant or breastfeeding Previous treatment with a specific BRAF or MEK inhibitor Receiving any other study agents Known brain metastases History of allergic reactions attributed to compounds of similar chemical or biologic composition to GSK2118436, bovine TSH, mannitol or iodine Active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs History of known glucose-6-phosphate dehyrogenase (G6PD) deficiency Corrected QT interval >/= 480 msecs; history of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks; Class II, III, or IV heart failure, abnormal cardiac valve morphology; or history of known cardiac arrhythmias Taking herbal remedies Subjects with significant symptoms from their thyroid cancer, or have a large burden of rapidly progressive iodine-refractory PTC who are in need of other systemic therapy, as judged by their treating physician


eligible ages (years): 18.0-37.0,  All  Infertility Obesity Indication for IVF/ICSI for the couple Woman's age >18< 38 years at randomization First, second or third IVF/ICSI treatment BMI > or = 30.0 <35.0 kg/m2 Willing to participate and to sign informed consent  Diabetes mellitus treated with insulin Oocyte or sperm donation planned Preimplantation genetic diagnosis (PGD) treatment planned Azoospermia known at randomization Patient not having adequate knowledge of Swedish (to understand patient information and questionnaires) QEWP-R questionnaire indicating binge eating disorder for the woman Previous participation in the study


eligible ages (years): 18.0-999.0,  All  Lacrimal Apparatus Disease Thyroid carcinoma Previous thyroidectomy  Potential causes of dry eye (autoimmune diseases, contact lens wearers or drugs that alter tear production, such as antihistamines and psychotropic) Use of other anti-neoplastic, such as 5-fluorouracil and docetaxel, which can cause epiphora and OVL Lacrimal gland / ocular trauma Radiation therapy for other diseases or radiotherapy of head and neck Patients with diseases that alter the neural control of tear secretion, hormone therapies, pterygium, Graves' disease with or without ophthalmopathy, blepharitis and other conditions that may reduce tear production or result in rapid evaporation


eligible ages (years): 18.0-999.0,  All  Graves' Hyperthyroidism Age 18 years or older Active Graves' hyperthyroidism (suppressed TSH (< 0.1) and positive TRAb) measured within the last two months prior to the date Written informed consent  Major co-morbidity, making the participants unlikely to continuously receive trial intervention in the intervention period Previous treatment with radioactive iodine Current ATD treatment having been received for more than two months Treatment with immunomodulatory drugs, such as cyclosporine A, methotrexate, cyclophosphamide Allergy towards the components in the selenium and placebo pills Pregnant or breast-feeding women Intake of selenium supplementation above 70 µg per day (70 µg corresponds to the amount in a multivitamin tablet) Unable to read and understand Danish Lack of informed consent


eligible ages (years): 18.0-70.0,  All  Obesity Major Depressive Disorder Dysthymic Disorder Cardiovascular Disease Female and male participants, with a BMI of 27 kg/m2 to 45 kg/m2 Age 18 years old Presence of current major depressive disorder or dysthymic disorder At least 2 CVD risk factors, as characterized by the metabolic syndrome, including Elevated waist circumference (males 40 inches or 102 cm; females 35 inches of 88 cm) Fasting blood glucose 100 mg/dL Blood pressure 130/85 mm Hg Triglycerides 150 mg/dL Reduced HDL cholesterol (males 40 mg/dL; females 50 mg/dL)  Cardiovascular event (e.g., myocardial infarction, stroke) within the past 12 months Use of tricyclic anti-depressants, monoamine oxidase inhibitors or paroxetine, mood stabilizers, or antipsychotic medications. (Note: participants who take SSRI/SNRI may be acceptable, provided they have been on a stable dose of these medications 3 months.) Use of weight-loss medications or any medications known to significantly affect weight (e.g., oral steroids) in past 3 months Weight loss of 5% or more in past 6 months Enrollment in weight reduction program in prior 3 months Treatment in individual psychotherapy for any psychiatric disorder in prior 3 months (Note: participants in couples or family counseling will be allowed.) Severe depression or severe impairment of functioning as judged by the assessor or PI Presence of active suicidal ideation Diabetes Alcohol/drug abuse/dependence


eligible ages (years): 21.0-65.0,  All  Overweight and Obesity age 21 to 65 BMI 25 to 45 sleep 7 hours or less most nights  use of medications affecting sleep sleep apnea shift work


eligible ages (years): 18.0-80.0,  All  Hypothyroidism radioiodine therapy after total thyroidectomy in differentiated thyroid cancer age over 18  kidney failure, liver failure, heart failure infection inflammation autoimmune disease other chronic disease


eligible ages (years): 6.0-9.0,  All  Hyperthyroid A-For the child born to hyperthyroid mother during pregnancy  oOld from 6 to 9 years included oAge of gestation between ≥37 and <41 weeks of amenorrhoea oBorn from a mono-foetale pregnancy oEuthyroïd at the time of the entry in the study oProvided education for at the elementary school on a level adapted to its age B-For hyperthyroid mother during pregnancy  oHyperthyroïd during pregnancy (transitory gestation hyperthyroid or disease of Basedow) oEuthyroïd at the time of the entry in the study C-For the child born to euthyroid mother during pregnancy  oOld from 6 to 9 years included oAge of gestation between ≥37 and <41 weeks of amenorrhoea oBorn from a mono-foetale pregnancy oEuthyroïd at the time of the entry in the study oProvided education for at the elementary school on a level adapted to its age D-For euthyroid mother during pregnancy  Euthyroïd at the time of the entry in the study  A-For the child born to hyperthyroid mother during pregnancy  Discovered of a thyroid dysfonction at the time of the entry in the study B-For hyperthyroid mother during pregnancy Discovered of a thyroid dysfonction at the time of the entry in the study C-For the child born to euthyroid mother during pregnancy Discovered of a thyroid dysfonction at the time of the entry in the study D-For euthyroid mother during pregnancy oDiscovered of a thyroid dysfonction at the time of the entry in the study oCarrying anti-TPO antibody at the time of the entry in the study


eligible ages (years): 18.0-999.0,  All  Atrial Fibrillation Subclinical Hyperthyroidism Atrial fibrillation or AV-nodal reentry tachycardia Fulfills for ablation (severe arrhythmia symptoms; for atrial fibrillation patients, having tried at least one antiarrhythmic agent with poor effect) Admitted for ablation for the first time Has left blood samples for thyroid status (TSH, free T4, free T3)  Atrial flutter Overt hyperthyroidism


eligible ages (years): 18.0-65.0,  All  Obesity, Morbid volunteers from Central Norway if female: taking oral contraceptives or post-menopausal body mass index 30-45 kg/m2 stable weight (<2kg variation in the last 3 months) not currently dieting to lose weight  Pregnancy breast feeding drug or alcohol abuse within the last two years current medication known to affect appetite or induce weight loss enrollment in another obesity treatment program history of psychological disorders history of eating disorders history of diabetes type 1 or 2 gastrointestinal disorders (particular cholelithiasis) kidney -, liver -, lung


eligible ages (years): 21.0-75.0,  All  Focus of Study: Prevent Pulling Sensation and/or Swallowing Difficulty in Patients Received Total Thyroidectomy. Age 21-75 Histological confirmation of differentiated thyroid cancer requiring surgery, symptomatic goiters, thyroid nodules requiring histological analysis, or thyrotoxicosis poorly controlled by medication Undergoing total thyroidectomy  Previous neck surgery Previous neck radiotherapy Patients with a known history of keloids Patients with a known history of motility disorders in the upper gastrointestinal tract and preexisting swallowing difficulty Patients with metastatic disease; patients with disease that would require postop radiation therapy, radionuclide iodine therapy and any adjuvant therapies Patients with advanced disease that would require radical or modified neck dissection Patients with lobe larger than 10 cm, or nodule larger than 8 cm which require extensive dissection that may confound the study Patients with connective tissue diseases and chronic diseases on long-term medications that may interfere with wound healings such as steroids


eligible ages (years): 20.0-45.0,  All  Healthy Pharmacokinetics of ASP7991 Healthy, as judged by the investigator/sub investigator based on the results of physical examination obtained before study drug administration Body weight: ≥50.0 kg, <80.0 kg BMI: ≥17.6, <26.4 Serum corrected calcium concentration: ≥9.0mg/dL, <10.4 mg/dL  Received any investigational drugs in other clinical or post-marketing studies within 120 days before screening Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before screening Received medication (including marketed drug) within 7 days before hospitalization, vitamin preparation including vitamin D and supplement including calcium or is scheduled to receive medication A deviation from normal range of 12-lead ECG (QT evaluation) A deviation from the normal range in clinical laboratory tests Highly sensitive cardiac troponin T (at screening): ≥0.014 ng/mL History of drug allergies Upper gastrointestinal disease (e.g. nausea, vomiting, stomachache) within 7 days before admission Concurrent or previous hepatic disease (e.g., viral hepatitis, drug-induced liver injury) Concurrent or previous endocrine disorders (e.g., hyperthyroidism, aberration in growth hormone)


eligible ages (years): 18.0-999.0,  All  Graves' Disease Out-patients 18 years of age or over, who have given written informed consent to participate in the study Diagnosed with Graves' disease Received radioiodine for treatment of Graves' disease Had a minimum of 12 months follow-up after RI Most recent RI dose 5 years ago or less at the time of enrollment  Patients unable to give informed consent Age 17 years or younger Cause of thyrotoxicosis other than Graves' disease Patients who have had more than one dose of radioiodine can only be included in the study once, using data pertaining to their most recent treatment episode Patients who might not adequately understand verbal explanations or written information given in English, or who have special communication needs


eligible ages (years): 45.0-999.0,  All  Hypertonia Resistant Hypertension > 140 / > 90mmHg age : 45 + Regular monitoring of blood levels considered pre-medication to lower blood pressure for at least 3 weeks before the preliminary investigation consistent Men and Women  derailed diabetes renal impairment , renal creatinine clear <50 ml Non austherapierte cancer / tumor patients Non adjusted thyroid dysfunction BMI> 35 LVEF <limit ( " 35% " ) Peripheral AVK ( ABI measurement ) > Stage II


eligible ages (years): 25.0-55.0,  All  Obesity MRI compatibility 55 yrs old 40 BMI weight stable right handed  MRI incompatibility left handed


eligible ages (years): 18.0-999.0,  All  Other Impaired Renal Function Disorder Normal Renal Function  Abnormal Renal Function Renal metastasis


eligible ages (years): 18.0-85.0,  All  Hyperthyroidism Hypothyroidism informed consent, female sex, age 20-85 years, indication for treatment of the thyroid disorder  pregnancy, renal insufficiency, known osteoporosis, other disease that may affect bone metabolism, medication which affects bone metabolism, T-score below -3.5, thyroidea ophthalmopathy with indication for steroids